Skip to content
Search

Latest Stories

Follow Us:
Top Stories

Dark magic: Drug companies and the art of deception

Dark magic: Drug companies and the art of deception
Getty Images

Pearl is a clinical professor of plastic surgery at the Stanford University School of Medicine and is on the faculty of the Stanford Graduate School of Business. He is a former CEO of The Permanente Medical Group.

Magicians know the key to a convincing trick is misdirection.


They instruct you to follow the left hand so that you’ll ignore the right, which is subtly palming a ball or pulling an ace from the sleeve. The art of the illusion hinges on the magician’s ability to divert attention from where the real action is happening. And, therefore, every illusion conceals the truth.

Similarly, the U.S. biopharmaceutical industry has relied on subtle forms of misdirection in response to increased scrutiny from Congress, the Biden administration and health policy experts.

Here are three illusions drug companies have crafted to maintain massive profitability:

Illusion No. 1: A Death-Defying Feat

Drug research and development (R&D) has, for decades, gifted humanity with medical wonders: antibiotics, statins, cancer therapies and HIV/AIDS treatments.

In the 21st century, however, drug innovation has slowed while pharma companies have made exorbitant pricing a key business strategy. Over the past 18 years, biopharma companies have earned an average gross profit margin of 77%. Last year, the five largest pharma firms generated more than $81.9 billion in profits.

To combat runaway drug prices, Congress passed the Inflation Reduction Act last year, allowing the U.S. government to negotiate prices for a limited number of expensive medications starting in 2026.

The pharmaceutical sector immediately filed lawsuits. In public remarks, drug spokespeople have created the illusion that any reduction in drug-industry profits will destroy R&D innovation and harm millions of patients.

The Hidden Truth

Hidden in this illusion are three facts drug companies don’t want Americans to know. Combined, these truths tell a different story about pharmaceutical research and development.

First, an overwhelming percentage of drug prices gets channeled into corporate profits and administrative costs, not R&D. In fact, a report during the height of the pandemic found that 7 in 10 major drug companies spent more on marketing and sales than R&D.

Second, research concludes that price constraints would minimally impact drug discovery. The Congressional Budget Office estimates that reducing the pharmaceutical revenues would result in just one less drug over the next decade and a total of 1% fewer medications over the next 30 years.

The third and most pernicious part of the illusion is getting people to ignore how many Americans are harmed by the unaffordability of life-essential medications. One example is insulin prices, which have tripled over the past decade. As a result, researchers from Yale found 25% of children with type 1 diabetes are given lower doses by their parents than their physicians recommend.

Nearly 1 in 4 Americans on prescription drugs now report difficulty affording their medications. That is the hidden truth. Exorbitant Rx prices hurt and kill far more Americans than the supposed loss of R&D ever would.

Illusion No. 2: The Statue Of Liberty Trick

Once Americans buy into the illusion that exorbitant drug prices are necessary to save lives, pharmaceutical companies move on to the next sleight of hand.

It goes like this: The United States, alone, must shoulder the enormous burden of drug prices.

Right now, Americans pay 2.4 to 3.4 times more for medications than in peer nations.

Much of the disparity in spending dates back to 2003 when Congress passed a law prohibiting the U.S. government from negotiating drug prices. And without any pricing regulations in place, domestic drug companies have pushed the boundaries ever higher. Over the past two years, nearly half of FDA approved medications have debuted above $150,000 with several topping $1 million per patient.

Outside of the United States, excessively high drug prices are a rarity.

Ozempic exemplifies the problem. This diabetes drug helps people lose significant weight while also avoiding heart attacks. A month’s supply of it costs $936 in the United States. In Japan, it sells for $169. It’s just $93 in the UK, $87 in Australia and $83 France.

Each of these countries has instituted drug-pricing controls and caps on drugmaker profits. If our nation adopted the same regulations, we could prescribe Ozempic to every overweight and obese American, and affordably solve the obesity epidemic. But under current retail pricing, doing so would increase drug spending $1.5 trillion per year, raising overall healthcare costs by 25%.

The Hidden Truth

The illusion here is that drug prices in other wealthy nations are non-negotiable.

But of course, that’s not accurate. American drug companies could play hardball with peer countries, refusing to sell their medications unless a more equitable pricing structure can be reached.

But why bother when you can simply stick Americans with the bill?

Illusion No. 3: What’s In Your Pocket?

When it comes to purchasing prescription drugs, there are two prices. There’s the very high retail price drug companies charge and the much-smaller amount insured patients pay when they pick up their medications (the out-of-pocket expense).

Since out-of-pockets are only small fraction of the total drug expense, drug companies would like Americans to concentrate on those dollars. But that requires people to assume the rest of the money—paid by the government or private businesses—is free.

The Hidden Truth

The reality is that workers and taxpayers wind up paying the price for expensive medications in two ways:

1. Workers earn less pay as benefit costs increase. That’s because employers treat wages and healthcare benefits as a single expense. As medical costs soar, raises disappear and salaries stagnate.

2. Taxpayers either pay more or get less. When medical costs rise, the government must either raise taxes or cut programs, including school funding and public safety.

Deception and misdirection can be sources of wonder at magic shows. But illusions in healthcare prove to be disturbing, dangerous and deadly.


Read More

​U.S. President Donald Trump sitting in the Oval Office.

U.S. President Donald Trump speaks during an announcement on American nuclear innovation in the Oval Office at the White House on July 24, 2026 in Washington, DC.

Eric Lee/Getty Images

Trump’s Elections Speech Was Not the Opening Shot; It was the Latest Salvo

President Donald Trump’s recent address repeating his claim that he won the 2020 election was widely portrayed as a dramatic escalation of his attacks on our election system. It wasn’t.

It is nothing new!

Keep ReadingShow less
  Creative Images Creative Images & Video Images Creative Editorial Video Creative Editorial  Search by image or video Close-up of woman holding a smartphone.

Can secure mobile voting expand election access? Explore how smartphone voting could increase turnout, improve accessibility, and modernize U.S. elections.

Sitthiphong/Getty Images

Mail-In Ballots Are Still Under Attack. Mobile Voting Can Protect Access To The Ballot Box.

Late last year, I became CEO of The Mobile Voting Project. Previously, I served as Chief of Staff to two United States senators, Chief of Staff at the US Department of Education, and Chief of Staff for Vice President Kamala Harris's presidential campaign. At every step in my public service career, I have always had one clear goal: making government work better for everyday people.

I believe that we cannot make government work better if we do not start at the very foundation of our government itself: democracy and voting. In my current role with The Mobile Voting Project, we are focused on making voting more seamless, secure, and accessible. We believe that putting democracy — literally — into the palms of every American’s hand is how we can boost turnout, reduce extremism, and strengthen our democracy.

Keep ReadingShow less
Congress Renews Talks on Prediction Market Reform As Some Companies Operate Under Loopholes

The House Subcommittee on Commodity Markets, Digital Assets and Rural Development met to hear from sports prediction market experts about U.S. regulations and protections on Tuesday, July 21, 2026.

Congress Renews Talks on Prediction Market Reform As Some Companies Operate Under Loopholes

WASHINGTON – Lawmakers considered whether the federal government needs to increase its regulation of sports prediction markets last Tuesday, just days after the end of the World Cup, the largest event ever for companies like Kalshi and Polymarket.

Traditional sports betting has grown exponentially in recent years, even though 11 states still ban it. But people in all 50 states can use prediction markets to win money on the outcome of certain events. The federal government regulates such trades, many of which surround sporting events.

Keep ReadingShow less
  Creative Images & Video Creative Images & Video Images Creative Editorial Video Creative Editorial  Search by image or video I Voted Today paper sticker on mans finger on rustic wooden table

How class, identity, and political recognition shaped the Democratic Party's relationship with rural white working-class voters over two decades.

BackyardProduction/Getty Images

The Thousand Injuries: The Not-Qwhite Voter and the Politics of Recognition

In the fall of 2003, Howard Dean said he wanted to be the candidate for guys with Confederate flags in the back windows of their pickup trucks. It was clumsy but not dishonest. He meant that his party had written off a whole category of American voter and wanted to change that. He was attacked at once, mostly by his own side, and walked it back within forty-eight hours. The lesson his party drew was not that the outreach had been badly phrased; It was that the outreach itself was impermissible, that to pursue the rural white working class voter was to be complicit with everything he was presumed to represent. Dean was the last major Democrat to try, and the consequences have accumulated in the shape of the electoral map.

Edgar Allan Poe understood something the party still does not. "The Cask of Amontillado" opens with a line that ought to hang in every campaign office: the thousand injuries of Fortunato the narrator had borne as best he could, but when Fortunato ventured upon insult, he vowed revenge. Injuries can be borne as long as the injured man believes his tormentors still regard his suffering as real. The insult is different. It reframes the injuries as deserved, telling the sufferer he is the kind of person who deserves to suffer. Poe's narrator does not recalculate his interests; he takes his revenge at great cost to himself. That is not irrational but human, and it is the most precise framework we have for what has happened to rural white working-class voters over the last twenty years.

Keep ReadingShow less